Liquid Biopsy with Plasma Epstein-Barr Virus DNA Characterizes Biological Relapse for the Prediction of Cancer Recurrence in Non-disseminated Nasopharyngeal Carcinoma

To investigate whether a bounce in plasma Epstein-Barr virus (EBV) DNA during posttreatment surveillance of nasopharyngeal carcinoma (NPC) informs the risk of clinical recurrence and its implication for early therapeutic intervention.